News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,384 Results
Type
Article (43821)
Company Profile (318)
Press Release (698231)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210993)
Career Advice (2113)
Deals (36759)
Drug Delivery (124)
Drug Development (83421)
Employer Resources (176)
FDA (16831)
Job Trends (15503)
News (357380)
Policy (34132)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2616)
Accelerated approval (34)
Adcomms (26)
Allergies (150)
Alliances (51584)
ALS (174)
Alzheimer's disease (1699)
Antibody-drug conjugate (ADC) (327)
Approvals (17096)
Artificial intelligence (543)
Autoimmune disease (162)
Automation (42)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (198)
Biotechnology (188)
Bladder cancer (160)
Brain cancer (61)
Breast cancer (655)
Cancer (4935)
Cardiovascular disease (421)
Career advice (1791)
Career pathing (37)
CAR-T (287)
CDC (49)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (36)
Clinical research (71210)
Collaboration (1776)
Company closure (4)
Compensation (1181)
Complete response letters (65)
COVID-19 (2788)
CRISPR (99)
C-suite (890)
Cystic fibrosis (148)
Data (6337)
Decentralized trials (2)
Denatured (36)
Depression (138)
Diabetes (510)
Diagnostics (6797)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (263)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (235)
Earnings (91992)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120363)
Executive appointments (1008)
FDA (20014)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1498)
Gene editing (206)
Generative AI (46)
Gene therapy (617)
GLP-1 (1015)
Government (4810)
Grass and pollen (7)
Guidances (385)
Healthcare (19066)
HIV (62)
Huntington's disease (46)
IgA nephropathy (86)
Immunology and inflammation (266)
Immuno-oncology (61)
Indications (119)
Infectious disease (3065)
Inflammatory bowel disease (201)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (259)
Interviews (328)
IPO (16921)
IRA (57)
Job creations (4070)
Job search strategy (1501)
JPM (64)
Kidney cancer (16)
Labor market (86)
Layoffs (576)
Leadership (34)
Legal (8425)
Liver cancer (92)
Longevity (16)
Lung cancer (665)
Lymphoma (385)
Machine learning (43)
Management (60)
Manufacturing (837)
MASH (170)
Medical device (13865)
Medtech (13921)
Mergers & acquisitions (20914)
Metabolic disorders (1311)
Multiple sclerosis (164)
NASH (17)
Neurodegenerative disease (328)
Neuropsychiatric disorders (92)
Neuroscience (2973)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4563)
Now hiring (68)
Obesity (620)
Opinion (289)
Ovarian cancer (168)
Pain (217)
Pancreatic cancer (232)
Parkinson's disease (286)
Partnered (34)
Patents (515)
Patient recruitment (502)
Peanut (60)
People (60952)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22103)
Phase 2 (31308)
Phase 3 (23460)
Pipeline (5491)
Policy (303)
Postmarket research (2655)
Preclinical (9390)
Press Release (68)
Prostate cancer (242)
Psychedelics (50)
Radiopharmaceuticals (290)
Rare diseases (880)
Real estate (6306)
Recruiting (72)
Regulatory (25453)
Reports (53)
Research institute (2441)
Resumes & cover letters (361)
Rett syndrome (27)
RNA editing (17)
RSV (81)
Schizophrenia (156)
Series A (246)
Series B (194)
Service/supplier (11)
Sickle cell disease (100)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3766)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (96)
The Weekly (78)
Vaccines (1043)
Venture capital (91)
Weight loss (405)
Women's health (94)
Worklife (18)
Date
Today (143)
Last 7 days (576)
Last 30 days (2370)
Last 365 days (30312)
2026 (4046)
2025 (30679)
2024 (35767)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27631)
2012 (29731)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (84)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (42171)
Australia (6753)
California (11465)
Canada (3342)
China (1143)
Colorado (483)
Connecticut (486)
Delaware (345)
Europe (90448)
Florida (1717)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (889)
India (72)
Indiana (537)
Iowa (22)
Japan (448)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1404)
Massachusetts (8249)
Michigan (330)
Minnesota (635)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (123)
New Hampshire (79)
New Jersey (3046)
New Mexico (29)
New York (3026)
North Carolina (1492)
North Dakota (8)
Northern California (5600)
Ohio (339)
Oklahoma (22)
Oregon (46)
Pennsylvania (2322)
Puerto Rico (24)
Rhode Island (48)
South America (1175)
South Carolina (68)
South Dakota (1)
Southern California (4468)
Tennessee (177)
Texas (1770)
United States (40761)
Utah (343)
Vermont (1)
Virginia (280)
Washington D.C. (81)
Washington State (937)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
742,384 Results for "crinetics pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March 2026
February 6, 2026
·
2 min read
Press Releases
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 7, 2026
·
6 min read
Press Releases
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
January 27, 2026
·
2 min read
Press Releases
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - January 5, 2026
January 6, 2026
·
5 min read
Rare diseases
FDA Approves Crinetics’ Once-Daily Acromegaly Treatment
The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with the rare pituitary condition. It’s the first approval for Crinetics Pharmaceuticals and something CEO Scott Struthers predicted “will transform people’s lives.”
September 25, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
December 19, 2025
·
1 min read
Press Releases
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12, 2026
January 13, 2026
·
2 min read
Rare diseases
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity.
January 7, 2026
·
2 min read
·
Dan Samorodnitsky
Press Releases
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 5, 2026
·
2 min read
Press Releases
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
·
11 min read
1 of 74,239
Next
